Pfizer (PFE) Says Lyrica Did Not Meet Primary Efficacy Endpoint in Phase 3
Get Alerts PFE Hot Sheet
Price: $26.27 -0.19%
Overall Analyst Rating:
NEUTRAL (= Flat)
Dividend Yield: 6.4%
Revenue Growth %: -23.7%
Overall Analyst Rating:
NEUTRAL (= Flat)
Dividend Yield: 6.4%
Revenue Growth %: -23.7%
Join SI Premium – FREE
Pfizer Inc. (NYSE: PFE) reports that a Phase 3 randomized withdrawal design study for Lyrica (pregabalin) in patients with inadequately treated painful diabetic peripheral neuropathy (pDPN) did not meet its primary efficacy endpoint, change in endpoint mean pain score relative to baseline. The study, A0081242, is a Phase 3b Multicenter, Double-Blind, Randomized Withdrawal Efficacy and Safety Study of Pregabalin in the Treatment of Patients with Inadequately Treated Painful Diabetic Peripheral Neuropathy.
Patients who had inadequate pain control while receiving a medication for pDPN were switched to Lyrica (150 or 300 mg/day) during a 6-week single-blind phase. Patients with ≥30% pain improvement were randomized to receive placebo or to continue treatment with Lyrica for the 13-week double-blind treatment phase.
665 patients received Lyrica in the single-blind phase of the study and had an improvement in single-blind endpoint mean pain score relative to baseline of 2.2 points (0-10 scale). Of the 294 patients who had ≥30% pain response and were randomized, Lyrica-treated patients had a total improvement in endpoint mean pain score of 3.9 points relative to baseline; however, this was not statistically significant compared to placebo (3.5 point total improvement). Further analyses will be conducted on these initial results.
The results for this study indicate that the most common adverse events in Lyrica-treated patients were peripheral edema, dizziness, somnolence and upper respiratory tract infection when compared with placebo. The adverse event profile is consistent with that known for Lyrica.
Patients who had inadequate pain control while receiving a medication for pDPN were switched to Lyrica (150 or 300 mg/day) during a 6-week single-blind phase. Patients with ≥30% pain improvement were randomized to receive placebo or to continue treatment with Lyrica for the 13-week double-blind treatment phase.
665 patients received Lyrica in the single-blind phase of the study and had an improvement in single-blind endpoint mean pain score relative to baseline of 2.2 points (0-10 scale). Of the 294 patients who had ≥30% pain response and were randomized, Lyrica-treated patients had a total improvement in endpoint mean pain score of 3.9 points relative to baseline; however, this was not statistically significant compared to placebo (3.5 point total improvement). Further analyses will be conducted on these initial results.
The results for this study indicate that the most common adverse events in Lyrica-treated patients were peripheral edema, dizziness, somnolence and upper respiratory tract infection when compared with placebo. The adverse event profile is consistent with that known for Lyrica.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
- Pfizer (PFE) Declares $0.42 Quarterly Dividend; 6.4% Yield
- Pfizer Declares Second-Quarter 2024 Dividend
Create E-mail Alert Related Categories
Corporate News, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!